RhumbLine Advisers’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $202M | Buy |
|
|||||
|
2025
Q1 | $219M | Buy |
|
|||||
|
2024
Q4 | $178M | Sell |
|
|||||
|
2024
Q3 | $209M | Sell |
|
|||||
|
2024
Q2 | $215M | Sell |
|
|||||
|
2024
Q1 | $194M | Buy |
|
|||||
|
2023
Q4 | $187M | Sell |
|
|||||
|
2023
Q3 | $161M | Buy |
|
|||||
|
2023
Q2 | $163M | Buy |
|
|||||
|
2023
Q1 | $142M | Buy |
|
|||||
|
2022
Q4 | $123M | Buy |
|
|||||
|
2022
Q3 | $118M | Buy |
|
|||||
|
2022
Q2 | $112M | Buy |
|
|||||
|
2022
Q1 | $99M | Sell |
|
|||||
|
2021
Q4 | $86.1M | Buy |
|
|||||
|
2021
Q3 | $69.9M | Sell |
|
|||||
|
2021
Q2 | $80.8M | Sell |
|
|||||
|
2021
Q1 | $109M | Sell |
|
|||||
|
2020
Q4 | $123M | Buy |
|
|||||
|
2020
Q3 | $141M | Sell |
|
|||||
|
2020
Q2 | $155M | Buy |
|
|||||
|
2020
Q1 | $120M | Buy |
|
|||||
|
2019
Q4 | $110M | Sell |
|
|||||
|
2019
Q3 | $86.6M | Buy |
|
|||||
|
2019
Q2 | $89.2M | Buy |
|
|||||
|
2019
Q1 | $88.4M | Buy |
|
|||||
|
2018
Q4 | $75.3M | Buy |
|
|||||
|
2018
Q3 | $86.3M | Sell |
|
|||||
|
2018
Q2 | $77M | Buy |
|
|||||
|
2018
Q1 | $71.8M | Sell |
|
|||||
|
2017
Q4 | $67.1M | Buy |
|
|||||
|
2017
Q3 | $65M | Buy |
|
|||||
|
2017
Q2 | $54.3M | Buy |
|
|||||
|
2017
Q1 | $45.8M | Buy |
|
|||||
|
2016
Q4 | $30.6M | Buy |
|
|||||
|
2016
Q3 | $34.7M | Buy |
|
|||||
|
2016
Q2 | $32.4M | Buy |
|
|||||
|
2016
Q1 | $28.7M | Buy |
|
|||||
|
2015
Q4 | $43.6M | Sell |
|
|||||
|
2015
Q3 | $36.2M | Buy |
|
|||||
|
2015
Q2 | $42.4M | Sell |
|
|||||
|
2015
Q1 | $40.6M | Buy |
|
|||||
|
2014
Q4 | $40.4M | Sell |
|
|||||
|
2014
Q3 | $38.9M | Sell |
|
|||||
|
2014
Q2 | $34.2M | Buy |
|
|||||
|
2014
Q1 | $25.2M | Buy |
|
|||||
|
2013
Q4 | $26.1M | Buy |
|
|||||
|
2013
Q3 | $21.4M | Sell |
|
|||||
|
2013
Q2 | $30.9M | Buy |
|